Skip to main content
Caplight Logo









Phinomics

Phinomics

Private
San Carlos, CaliforniaHealthcare & Life Scienceshttps://www.phinomics.com/

Last Round

Grant

May 15, 2023

Total Funding Raised

$1.13M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Phinomics is a biotechnology company developing genomic technologies designed to create circular deoxyribonucleic acid systems for unmet needs in healthcare.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Healthcare Analytics, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service, Government Contracts

AI Layer

Application

Keywords

ecDNA analysiscircular DNA analysisecDNAextrachromosomal circular DNAbiomarker discoverytherapeutic target discoveryprecision oncologyAI-driven drug discoverycirculome analysiscancer intelligence platformpredictive biomarkersdrug discovery platformliquid biopsysingle-cell analysispatient stratification

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Phinomics Comparables

Compare Phinomics with similar companies based on industry and business-model similarity.

Phinomics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SOPHiA GENETICS
70%
CircNova
67%
Personalis Inc
64%

Phinomics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 15, 2023
SeedDec 31, 2022

Key People

Founding team and executive leadership

Stephen Levene

Co-founder And CTO

Founding Team

Phinomics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 22, 2026

    Grew 33% QoQ, from 9 to 12 employees.

  • Jun 27, 2026

    Grew 50% QoQ, from 8 to 12 employees.

Phinomics Filings

Explore SEC and related filing metadata, where available.

Phinomics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Phinomics's valuation, stock price, and market status.

Is Phinomics a public or private company?

Phinomics is a private company.

What is the current stock price of Phinomics?

Phinomics is a private company with no public stock price. No recent secondary market data is available.

How much is Phinomics worth (valuation)?

Valuation information for Phinomics is not publicly available.

Can I buy Phinomics stock?

Phinomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Phinomics's last funding round?

Phinomics's most recent funding round was Grant on May 15, 2023.

Who are the main investors in Phinomics?

Key investors in Phinomics include National Cancer Institute, NIH RADx, Creative Destruction Lab, The Elizabeth Elting Venture Fund, K5 Global.

Will Phinomics IPO soon?

No public IPO plans have been announced for Phinomics.

How can I track Phinomics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Phinomics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Carlos, California
Employee Range9
Year Founded2020
Last FundingMay 15, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?